Journals / Anadolu Kardiyoloji Dergisi / 2014 / Cilt: 14 - Sayı: 2

Approach to cases with resistant hypertension

Pages
192–195
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Diagnostic workup and management of resistant hypertension were discussed in different clinical presentations. (Anadolu Kardiyol Derg 2014; 14: 192-5)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Resistant hypertension is defined as blood pressure that remains above 140/90 mm Hg despite the concurrent use of optimal dose of 3 antihy- pertensive agents of different classes.
📊
Key Findings & Data:Ideally, 1 of these 3 agents should be a diuretic agent.
💡
Conclusion & Impact:Diagnostic workup and management of resistant hypertension were discussed in different clinical presentations. (Anadolu Kardiyol Derg 2014; 14: 192-5)
🔬Design:Research Article
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Resistant hypertension is defined as blood pressure that remains above 140/90 mm Hg despite the concurrent use of optimal dose of 3 antihy- pertensive agents of different classes. Ideally, 1 of these 3 agents should be a diuretic agent. The etiology of resistance hypertension is multi- factorial. Successful treatment requires identification and reversal of lifestyle factors (obesity, dietary salt intake, alcohol intake, lack of adher- ence to prescribed medicines, and interfering substances), and to exclude the presence of pseudoresistance. Once confounding factors have been ruled out, evaluation for potentially treatable secondary causes of hypertension should be considered. Most forms of secondary hyperten- sion are related with adrenal or renal disorders such as primary hyperaldosteronism and renovascular disease. Although, obstructive sleep apnea syndrome is not a typical cause of secondary hypertension, it is commonly present in resistant hypertension. Diagnostic workup and management of resistant hypertension were discussed in different clinical presentations. (Anadolu Kardiyol Derg 2014; 14: 192-5)

🔖

Cite This Article

TORUN, D. (2022). Approach to cases with resistant hypertension. Anadolu Kardiyoloji Dergisi, Cilt: 14 - Sayı: 2, 192–195. https://ajindex.com/articles/436121

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52. [CrossRef] 2. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP Toto RD, et al., Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 24; 117: 510-26. [CrossRef] 3. Sarwar MS, İslam MS, Al Baker SM, Hasnat A. Resistant hypertension: underlying cause and treatment. Drug Res (Stuttg) 2013; 63: 217-23. [CrossRef] 4. Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009; 54: 475-81. [CrossRef] 5. Herrmann SM, Textor SC. Diagnostic criteria for renovascular disease: where are we now? Nephrol Dial Transplant 2012; 27: 2657-63. [CrossRef] 6. Bosmans JL, De Broe ME. Renovascular hypertension: diagnostic and therapeutic challenges. JBR-BTR 2004; 87: 32-5. 7. Plouin PF, Amar L, Chatellier G. Trends in the prevalence of primary aldosteronism, aldosterone-producing adenomas, and surgically correctable aldosterone-dependent hypertension. Nephrol Dial Transplant 2004; 19: 774-7. [CrossRef] 8. Rossi GP Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al., PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol 2006 5; 48: 2293-300. [CrossRef] 9. Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient's cohorts and in population-based studies--a review of the current literature. HormMetab Res 2012; 44: 157-62. [CrossRef] 10. Calhoun DA. Hyperaldosteronism as a common cause of resistant hypertension. Annu Rev Med 2013; 64: 233-47. [CrossRef] 11. Mulatero P Monticone S, Veglio F. Diagnosis and treatment of primary, aldosteronism. Rev Endocr Metab Disord 2011; 12: 3-9. [CrossRef] 12. Manni R, Politini L, Ratti MT, Tartara A. Sleepiness in obstructive sleep apnea syndrome and simple snoring evaluated by the Epworth Sleepiness Scale. J Sleep Res 1999; 8: 319-20. [CrossRef] 13. Somers VK, White DP Amin R, Abraham WT, Costa F, Culebras A, et, al. Sleep apnea and cardiovascular disease: an American Heart Associa